Core Insights - ModeX Therapeutics Inc., a subsidiary of OPKO Health, has established a Scientific Advisory Board to enhance its immunology and oncology pipeline, focusing on multispecific antibodies and vaccines [1][3][9] - The board consists of prominent scientists recognized for their contributions to biomedical research and therapeutic advancements [2][4][5] Company Overview - ModeX is a clinical-stage biopharmaceutical company developing proprietary multispecific therapeutics using its MSTAR platform, which allows for the creation of antibodies that can target four or more disease pathways [9] - The company is focused on addressing complex diseases, including various forms of cancer and immune-mediated diseases, with a promising pipeline of first-in-class drugs [1][8][9] Scientific Advisory Board - The founding members of the board include Drs. John Heymach, Ronald Levy, Myron Cohen, and Rafi Ahmed, all of whom are leaders in their respective fields [2][4][6] - The board aims to guide ModeX in advancing next-generation immune therapies that can target multiple disease pathways simultaneously [3][5] Multispecific Therapeutics - Multispecific therapeutics are positioned as the future of medicine, addressing the limitations of traditional single-target therapies by combining multiple biological targets [8] - ModeX's approach aims to revolutionize treatment options for patients suffering from complex and previously untreatable conditions [8][9]